BACKGROUND: Our purpose in this study was to assess the postoperative subjective and objective results after implantation of the Acrysof ReSTOR lens and to evaluate the advantages and limitations of the apodized diffractive optic design of this new multifocal intraocular lens (MIOL). METHODS: Phakoemulsification and implantation of an Acrysof ReSTOR was performed in 55 eyes of 32 patients. All patients were examined after a mean period of 7.9+/-1.9 months. The accuracy of lens calculation was evaluated for the Haigis, Holladay I, and SRK-T formulas. Uncorrected and corrected visual acuity for distance and for intermediate and near vision were assessed, as was stereoacuity. In addition, contrast sensitivity was tested under photopic and mesopic conditions, with and without glare. The patients were asked about dysphotic phenomena such as halos, glare or flare, and night vision using a standardized evaluation. The degree to which patients were able to manage without spectacles after the surgery was also documented. RESULTS: The median monocular uncorrected visual acuity (UCVA) for distance was 20/25 (LogMAR 0.05) while the binocular UCVA was 20/20 (LogMAR 0). The monocular uncorrected acuity for near vision was 20/25 (LogMAR 0.1), the binocular near visual acuitiy was 20/20 (LogMAR 0), while the intermediate monocular visual acuity was 20/50 (LogMAR 0.4) and the binocular, 20/32 (LogMAR 0.2). Contrast sensitivity was within the normal range. Dysphotic phenomena were noted by 66% of patients but were so slight as not to cause any problem at all in 59%. For close work and distance vision 84% of all patients needed no correcting glasses, while 78% did not need to use glasses for intermediate vision. CONCLUSION: The Acrysof ReSTOR provides excellent uncorrected visual acuity for distance and near vision and the level of patient satisfaction achieved with it is good.
BACKGROUND: Our purpose in this study was to assess the postoperative subjective and objective results after implantation of the Acrysof ReSTOR lens and to evaluate the advantages and limitations of the apodized diffractive optic design of this new multifocal intraocular lens (MIOL). METHODS: Phakoemulsification and implantation of an Acrysof ReSTOR was performed in 55 eyes of 32 patients. All patients were examined after a mean period of 7.9+/-1.9 months. The accuracy of lens calculation was evaluated for the Haigis, Holladay I, and SRK-T formulas. Uncorrected and corrected visual acuity for distance and for intermediate and near vision were assessed, as was stereoacuity. In addition, contrast sensitivity was tested under photopic and mesopic conditions, with and without glare. The patients were asked about dysphotic phenomena such as halos, glare or flare, and night vision using a standardized evaluation. The degree to which patients were able to manage without spectacles after the surgery was also documented. RESULTS: The median monocular uncorrected visual acuity (UCVA) for distance was 20/25 (LogMAR 0.05) while the binocular UCVA was 20/20 (LogMAR 0). The monocular uncorrected acuity for near vision was 20/25 (LogMAR 0.1), the binocular near visual acuitiy was 20/20 (LogMAR 0), while the intermediate monocular visual acuity was 20/50 (LogMAR 0.4) and the binocular, 20/32 (LogMAR 0.2). Contrast sensitivity was within the normal range. Dysphotic phenomena were noted by 66% of patients but were so slight as not to cause any problem at all in 59%. For close work and distance vision 84% of all patients needed no correcting glasses, while 78% did not need to use glasses for intermediate vision. CONCLUSION: The Acrysof ReSTOR provides excellent uncorrected visual acuity for distance and near vision and the level of patient satisfaction achieved with it is good.
Authors: Jorge L Alió; Marco Tavolato; Fernando De la Hoz; Pascual Claramonte; José-Luis Rodríguez-Prats; Ahmed Galal Journal: J Cataract Refract Surg Date: 2004-12 Impact factor: 3.351
Authors: John D Hunkeler; Tom M Coffman; Jerry Paugh; Alan Lang; Pamela Smith; Nicholas Tarantino Journal: J Cataract Refract Surg Date: 2002-07 Impact factor: 3.351